Published in J Clin Psychiatry on April 01, 2008
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA (2009) 6.91
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry (2011) 2.75
Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis. Schizophr Bull (2011) 1.98
Metabolic syndrome in people with schizophrenia: a review. World Psychiatry (2009) 1.96
Inequalities in healthcare provision for people with severe mental illness. J Psychopharmacol (2010) 1.93
Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology (2010) 1.67
Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry (2010) 1.65
Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull (2014) 1.60
Antipsychotic drugs and obesity. Trends Mol Med (2010) 1.21
Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: a systematic review. Int J Behav Nutr Phys Act (2011) 1.08
Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: results from the WHO World Health Survey. World Psychiatry (2013) 1.07
Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry (2012) 1.06
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. BMC Gastroenterol (2011) 1.03
Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One (2014) 1.02
Feasibility of the Walk, Address, Learn and Cue (WALC) Intervention for schizophrenia spectrum disorders. Arch Psychiatr Nurs (2009) 1.00
The influence of health disparities on targeting cancer prevention efforts. Am J Prev Med (2014) 0.98
Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. Front Neurosci (2015) 0.97
Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues Clin Neurosci (2011) 0.94
Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract (2009) 0.93
The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci (2014) 0.91
Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci (2010) 0.91
Oral health status and treatment needs among psychiatric inpatients in Rennes, France: a cross-sectional study. BMC Psychiatry (2013) 0.90
Care for patients with severe mental illness: the general practitioner's role perspective. BMC Fam Pract (2009) 0.89
Improvement of care for the physical health of patients with severe mental illness: a qualitative study assessing the view of patients and families. BMC Health Serv Res (2013) 0.87
Efficacy of lifestyle interventions in physical health management of patients with severe mental illness. Ann Gen Psychiatry (2011) 0.84
Quality assurance in psychiatry: quality indicators and guideline implementation. Eur Arch Psychiatry Clin Neurosci (2009) 0.83
Excess mortality due to depression and anxiety in the United States: results from a nationally representative survey. Gen Hosp Psychiatry (2015) 0.83
Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study. Ther Adv Psychopharmacol (2011) 0.82
S3 guideline on psychosocial therapies in severe mental illness: evidence and recommendations. Eur Arch Psychiatry Clin Neurosci (2014) 0.82
Motivating Persons with Schizophrenia Spectrum Disorders to Exercise: Rationale and Design. Clin Schizophr Relat Psychoses (2009) 0.81
A 52-week, double-blind evaluation of the metabolic effects of aripiprazole and lithium in bipolar I disorder. Prim Care Companion CNS Disord (2011) 0.80
Risk of acute complications of diabetes among people with schizophrenia in Ontario, Canada. Diabetes Care (2010) 0.80
Development of an integrated psychosocial treatment to address the medical burden associated with bipolar disorder. J Psychiatr Pract (2011) 0.80
Examining the cost effectiveness of interventions to promote the physical health of people with mental health problems: a systematic review. BMC Public Health (2013) 0.79
Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial. PLoS One (2015) 0.78
Accuracy of self-reported medical problems in patients with alcohol dependence and co-occurring schizophrenia or schizoaffective disorder. Schizophr Res (2011) 0.78
Assessment of physical illness by mental health clinicians during intake visits. Psychiatr Serv (2010) 0.78
Physical disease in schizophrenia: a population-based analysis in Spain. BMC Public Health (2010) 0.77
Psychophysiologic treatment for patients with medically unexplained symptoms: a randomized controlled trial. Psychosomatics (2011) 0.77
Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders. Schizophr Res (2015) 0.77
Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Transl Psychiatry (2013) 0.77
Towards Horizon 2020: challenges and advances for clinical mental health research - outcome of an expert survey. Neuropsychiatr Dis Treat (2014) 0.77
Quality assessment of physical activity recommendations within clinical practice guidelines for the prevention and treatment of cardio-metabolic risk factors in people with schizophrenia. Community Ment Health J (2011) 0.77
Lithium Nephrotoxicity: When Is the Time for Nephrology Consultation? Iran J Public Health (2016) 0.75
Diabetes and Cardiovascular Care Among People with Severe Mental Illness: A Literature Review. J Gen Intern Med (2016) 0.75
Do routine outcome monitoring results translate to clinical practice? A cross-sectional study in patients with a psychotic disorder. BMC Psychiatry (2016) 0.75
Lower Incidence of End-Stage Renal Disease but Suboptimal Pre-Dialysis Renal Care in Schizophrenia: A 14-Year Nationwide Cohort Study. PLoS One (2015) 0.75
The importance of negative comorbidity. J Clin Psychiatry (2009) 0.75
Improving physical health for people taking antipsychotic medication in the Community Learning Disabilities Service. BMJ Qual Improv Rep (2016) 0.75
The role of boundary spanners in delivering collaborative care: a process evaluation. BMC Fam Pract (2016) 0.75
Searching for serendipity. J Clin Psychiatry (2011) 0.75
Weight Gain and Its Correlates Among Forensic Inpatients. Can J Psychiatry (2015) 0.75
Aminotransferase levels as a prospective predictor for the development of metabolic syndrome in patients with schizophrenia. Psychopharmacology (Berl) (2014) 0.75
Toward the Identification of a Specific Psychopathology of Substance Use Disorders. Front Psychiatry (2017) 0.75
Opportunities for Integrating Physical Health Within Assertive Community Treatment Teams: Results from Practitioner Focus Groups. Community Ment Health J (2016) 0.75
Serious mental illness and medical comorbidities: Findings from an integrated health care system. J Psychosom Res (2017) 0.75
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
No health without mental health. Lancet (2007) 15.22
Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 13.63
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med (2006) 10.89
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med (2005) 8.52
Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet (2013) 8.02
Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey. Lancet (2009) 7.32
Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry (2004) 6.40
Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet (2009) 6.13
Failure and delay in initial treatment contact after first onset of mental disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry (2005) 6.03
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry (2007) 5.64
The most expensive medical conditions in America. Health Aff (Millwood) (2002) 5.50
National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry (2007) 5.49
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry (2011) 5.46
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry (2002) 5.14
Global pattern of experienced and anticipated discrimination reported by people with major depressive disorder: a cross-sectional survey. Lancet (2012) 4.79
Sudden death and use of stimulant medications in youths. Am J Psychiatry (2009) 4.33
Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry (2005) 4.28
Boundary and medial shape analysis of the hippocampus in schizophrenia. Med Image Anal (2004) 4.25
Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res (2011) 4.22
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull (2003) 4.13
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry (2006) 4.12
Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry (2002) 3.71
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry (2006) 3.66
Changing profiles of service sectors used for mental health care in the United States. Am J Psychiatry (2006) 3.64
Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry (2004) 3.59
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord (2009) 3.56
Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry (2009) 3.56
Physical health monitoring of patients with schizophrenia. Am J Psychiatry (2004) 3.54
Mental health of college students and their non-college-attending peers: results from the National Epidemiologic Study on Alcohol and Related Conditions. Arch Gen Psychiatry (2008) 3.52
Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year outcomes of a randomised clinical trial. Br J Psychiatry (2011) 3.49
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry (2008) 3.48
Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry (2006) 3.35
Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30
Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study. J Clin Psychiatry (2006) 3.28
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res (2010) 3.26
Trends in care by nonphysician clinicians in the United States. N Engl J Med (2003) 3.24
Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. Nord J Psychiatry (2005) 3.22
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 3.21
Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry (2008) 3.15
Service utilization for lifetime mental disorders in U.S. adolescents: results of the National Comorbidity Survey-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry (2010) 3.14
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry (2006) 3.12
Acamprosate for alcohol dependence. Cochrane Database Syst Rev (2010) 3.03
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord (2012) 3.01
A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry (2004) 3.00
Severe mental illness and risk of cardiovascular disease. JAMA (2007) 2.93
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res (2005) 2.91
Interventions to improve medication adherence in schizophrenia. Am J Psychiatry (2002) 2.78
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry (2007) 2.75
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry (2011) 2.75
Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation (2003) 2.73
Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. Proc Natl Acad Sci U S A (2005) 2.73
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology (2006) 2.70
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry (2007) 2.68
Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry (2005) 2.63
Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. J Neurosci (2007) 2.61
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res (2006) 2.60
Do patients with schizophrenia wish to be involved in decisions about their medical treatment? Am J Psychiatry (2005) 2.55
National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry (2012) 2.52
Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry (2002) 2.52
Declining use of electroconvulsive therapy in United States general hospitals. Biol Psychiatry (2012) 2.50
Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull (2010) 2.50
Effectiveness of switching antipsychotic medications. Am J Psychiatry (2006) 2.38
Medication costs, adherence, and health outcomes among Medicare beneficiaries. Health Aff (Millwood) (2003) 2.37
Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry (2013) 2.34
Obesity among those with mental disorders: a National Institute of Mental Health meeting report. Am J Prev Med (2009) 2.34
Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2009) 2.33
When does depression become a mental disorder? Br J Psychiatry (2011) 2.33
Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron (2013) 2.32
Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull (2012) 2.30
Antidepressant drug compliance: reduced risk of MI and mortality in depressed patients. Am J Med (2011) 2.29
Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) (2009) 2.29
Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry (2007) 2.25
Effectiveness of electroconvulsive therapy in community settings. Biol Psychiatry (2004) 2.24
The national cholesterol education program diet vs a diet lower in carbohydrates and higher in protein and monounsaturated fat: a randomized trial. Arch Intern Med (2004) 2.24
A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry (2006) 2.23
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry (2007) 2.22
Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev (2010) 2.21
Iatrogenic stigma of mental illness. BMJ (2002) 2.21
Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet (2011) 2.21
The WPA-WHO Global Survey of Psychiatrists' Attitudes Towards Mental Disorders Classification. World Psychiatry (2011) 2.18
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord (2009) 2.17
Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry (2007) 2.15
The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry (2003) 2.15
Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev (2010) 2.13
The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis (2008) 2.13
COMT Val(158)Met and BDNF C(270)T polymorphisms in schizophrenia: a case-control study. Schizophr Res (2005) 2.12
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry (2008) 2.10